Clinical Trials In Delaware

Discover hundreds of clinical trials in Delaware.
Search clinical trials in Delaware by city, condition or phase.

e.g. Respiratory Diseases

Delaware•Healthy volunteers: No

Filter results

Results: 263

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

Recruiting

Phase 3

Sponsor:

Bristol-Myers Squibb

Location:

Newark, Birmingham, Jasper, Phoenixshow 72 more

Code:

NCT06003426

Conditions

Idiopathic Pulmonary Fibrosis

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Interventions

BMS-986278

BMS-986278 Placebo

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Recruiting

Phase 3

Sponsor:

SWOG Cancer Research Network

Location:

Wilmington, Seaford, Rehoboth Beach, Newarkshow 495 more

Code:

NCT04071457

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Lenalidomide

Daratumumab/rHuPH20

University of Delaware Parkinson's Disease Registry

Recruiting

Sponsor:

University of Delaware

Location:

Newark

Code:

NCT04496973

Conditions

Parkinson Disease

Eligibility Criteria

Sex: All

Age: 21 - 70+

Healthy Volunteers: Not accepted

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

Recruiting

Phase 3

Sponsor:

National Cancer Institute (NCI)

Location:

Wilmington, Birmingham, Mesa, Phoenixshow 95 more

Code:

NCT03871257

Conditions

Low Grade Glioma

Neurofibromatosis Type 1

Visual Pathway Glioma

Eligibility Criteria

Sex: All

Age: 2 - 21

Healthy Volunteers: Not accepted

Interventions

Carboplatin

Magnetic Resonance Imaging

Quality-of-Life Assessment

Questionnaire Administration

Selumetinib Sulfate

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Recruiting

Phase 3

Sponsor:

Bristol-Myers Squibb

Location:

Newark, Mobile, Cerritos, Irvineshow 17 more

Code:

NCT05552976

Conditions

Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Mezigdomide

Carfilzomib

Dexamethasone

e.g. Respiratory Diseases

Delaware•Healthy volunteers: No

Filter results

Results: 263

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

Recruiting

Phase 3

Sponsor:

Bristol-Myers Squibb

Location:

Newark, Birmingham, Jasper, Phoenixshow 72 more

Code:

NCT06003426

Conditions

Idiopathic Pulmonary Fibrosis

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Interventions

BMS-986278

BMS-986278 Placebo

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Recruiting

Phase 3

Sponsor:

SWOG Cancer Research Network

Location:

Wilmington, Seaford, Rehoboth Beach, Newarkshow 495 more

Code:

NCT04071457

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Lenalidomide

Daratumumab/rHuPH20

University of Delaware Parkinson's Disease Registry

Recruiting

Sponsor:

University of Delaware

Location:

Newark

Code:

NCT04496973

Conditions

Parkinson Disease

Eligibility Criteria

Sex: All

Age: 21 - 70+

Healthy Volunteers: Not accepted

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

Recruiting

Phase 3

Sponsor:

National Cancer Institute (NCI)

Location:

Wilmington, Birmingham, Mesa, Phoenixshow 95 more

Code:

NCT03871257

Conditions

Low Grade Glioma

Neurofibromatosis Type 1

Visual Pathway Glioma

Eligibility Criteria

Sex: All

Age: 2 - 21

Healthy Volunteers: Not accepted

Interventions

Carboplatin

Magnetic Resonance Imaging

Quality-of-Life Assessment

Questionnaire Administration

Selumetinib Sulfate

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Recruiting

Phase 3

Sponsor:

Bristol-Myers Squibb

Location:

Newark, Mobile, Cerritos, Irvineshow 17 more

Code:

NCT05552976

Conditions

Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Mezigdomide

Carfilzomib

Dexamethasone